Publication:
High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study

Simple item page
dc.contributor.authorGÜNDÜZ, FEYZA
dc.contributor.authorsGonen, Can; Gunduz, Feyza; Doganay, Levent; Enc, Feruze Y.; Yegin, Ender G.; Ahishali, Emel; Erdem, Emrullah; Sokmen, Mehmet; Tuncer, Ilyas; Ozdogan, Osman
dc.date.accessioned2022-03-12T20:26:52Z
dc.date.available2022-03-12T20:26:52Z
dc.date.issued2015
dc.description.abstractObjectiveLow baseline viremia and an early treatment response predict the best outcomes in hepatitis B virus (HBV)-infected patients treated with nucleoside analogues with low barriers to resistance. The aim of this study was to assess the long-term results and effectiveness of lamivudine in patients with low baseline viremia and early virological treatment response. MethodsIn this multicenter, real-life setting study, 111 antiviral-naive patients with low baseline viremia (HBV DNA <10(7) copies/mL) plus an early virological response (HBV DNA <300 copies/mL at week 24) treated with lamivudine were enrolled. The primary end-point was treatment failure, defined as the re-emergence of detectable viremia or at least a 1 log increase in HBV DNA, resulting in a titer of 300 copies/mL with lamivudine treatment after week 24, which required treatment modification. ResultsAltogether 111 patients, including 78 non-cirrhotic and 33 cirrhotic patients, were included in the study. Treatment failure occurred in 30.8% of the non-cirrhotic patients over a median follow-up period of 32.5 months, and the 1-, 2-, 3-, 4- and 5-year treatment failure rates were 6.5%, 14.0%, 31.4%, 39.6% and 43.1%, respectively. Treatment failure occurred in 28.8% of the whole group. There were no differences between the cirrhotic and non-cirrhotic patients. ConclusionsLamivudine treatment had a high treatment modification rate in patients with low baseline viremia and early virological response over a long-term follow-up in a real-life setting. The pretreatment and on-treatment favorable characteristics found in the studies with telbivudine appeared to be inapplicable to lamivudine.
dc.identifier.doi10.1111/1751-2980.12237
dc.identifier.eissn1751-2980
dc.identifier.issn1751-2972
dc.identifier.pubmed25708813
dc.identifier.urihttps://hdl.handle.net/11424/233575
dc.identifier.wosWOS:000355284300006
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofJOURNAL OF DIGESTIVE DISEASES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectearly response
dc.subjecthepatitis B virus
dc.subjectlamivudine
dc.subjectresistance
dc.subjectviral load
dc.subjectCHRONIC HEPATITIS-B
dc.subjectSURFACE-ANTIGEN
dc.subjectVIRUS-DNA
dc.subjectBREAKTHROUGH
dc.titleHigh treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study
dc.typearticle
dspace.entity.typePublication
local.avesis.idb8376ba6-77aa-4df0-b1a9-998654bfa7a3
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages7
oaire.citation.endPage292
oaire.citation.issue5
oaire.citation.startPage286
oaire.citation.titleJOURNAL OF DIGESTIVE DISEASES
oaire.citation.volume16
relation.isAuthorOfPublicationd48af87b-516f-4788-b8af-58d60d712c5e
relation.isAuthorOfPublication.latestForDiscoveryd48af87b-516f-4788-b8af-58d60d712c5e

Files

Collections

Research Outputs